At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
RPRX Royalty Pharma plc
Market Closed 12-20 16:00:00 EST
24.92
+0.64
+2.64%
盘后25.01
+0.09+0.36%
19:52 EST
High25.00
Low24.32
Vol7.57M
Open24.34
D1 Closing24.28
Amplitude2.82%
Mkt Cap11.07B
Tradable Cap9.57B
Total Shares444.30M
T/O188.55M
T/O Rate1.97%
Tradable Shares383.92M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
Here's Why Agios Stock Plummeted More Than 20% on Monday
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 35 marketed therapies and 10 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neurology, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.